SB-612,111

SB-612,111 is an opioid receptor ligand which is a potent and selective antagonist for the nociceptin receptor (ORL-1), several times more potent than the older drug J-113,397.[1] It does not have analgesic effects in its own right, but prevents the development of hyperalgesia,[2] and also shows antidepressant effects in animal studies.[3]

SB-612,111
Clinical data
Other namesSB-612,111
Identifiers
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC24H29Cl2NO
Molar mass418.40 g·mol−1
3D model (JSmol)
 NY (what is this?)  (verify)

See also

References

  1. Spagnolo B, Carrà G, Fantin M, Fischetti C, Hebbes C, McDonald J, et al. (June 2007). "Pharmacological characterization of the nociceptin/orphanin FQ receptor antagonist SB-612111 [(-)-cis-1-methyl-7-4-(2,6-dichlorophenyl)piperidin-1-yl]methyl]-6,7,8,9-tetrahydro-5H-benzocyclohepten-5-ol]: in vitro studies". The Journal of Pharmacology and Experimental Therapeutics. 321 (3): 961–7. doi:10.1124/jpet.106.116764. PMID 17329552. S2CID 17504101.
  2. Zaratin PF, Petrone G, Sbacchi M, Garnier M, Fossati C, Petrillo P, et al. (February 2004). "Modification of nociception and morphine tolerance by the selective opiate receptor-like orphan receptor antagonist (-)-cis-1-methyl-7-4-(2,6-dichlorophenyl)piperidin-1-yl]methyl]-6,7,8,9-tetrahydro-5H-benzocyclohepten-5-ol (SB-612111)". The Journal of Pharmacology and Experimental Therapeutics. 308 (2): 454–61. doi:10.1124/jpet.103.055848. PMID 14593080. S2CID 8036750.
  3. Rizzi A, Gavioli EC, Marzola G, Spagnolo B, Zucchini S, Ciccocioppo R, et al. (June 2007). "Pharmacological characterization of the nociceptin/orphanin FQ receptor antagonist SB-612111 [(-)-cis-1-methyl-7-4-(2,6-dichlorophenyl)piperidin-1-yl]methyl]-6,7,8,9-tetrahydro-5H-benzocyclohepten-5-ol]: in vivo studies". The Journal of Pharmacology and Experimental Therapeutics. 321 (3): 968–74. doi:10.1124/jpet.106.116780. PMID 17329551. S2CID 2557475.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.